The improvement of sulforaphane in type 2 diabetes mellitus (T2DM) and related complications: A review*

被引:20
作者
Wang, Mengjiao [1 ]
Chen, Min [2 ]
Guo, Rui [1 ]
Ding, Yangyang [2 ]
Zhang, Haihui [1 ]
He, Yuanqing [1 ,2 ]
机构
[1] Jiangsu Univ, Coll Food Sci & Biol Engn, Zhenjiang 212013, Peoples R China
[2] Jiangsu Univ, Lab Anim Res Ctr, Zhenjiang 212013, Peoples R China
关键词
Type 2 diabetes mellitus; Sulforaphane; Hypoglycemic; Insulin resistance; INSULIN-RESISTANCE; OXIDATIVE STRESS; BROCCOLI SPROUTS; ADIPOSE-TISSUE; GROWTH-FACTOR; DIET RICH; NRF2; EXPRESSION; INFLAMMATION; NEPHROPATHY;
D O I
10.1016/j.tifs.2022.10.007
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Background: Type 2 diabetes mellitus (T2DM), one type of disease with severe disorders of endocrine and metabolism, can induce lethal complications in various organs. Currently, most of the treatment for T2DM are accompanied with side effects. However, natural active ingredients, including sulforaphane have been demonstrated their beneficial effects on the prevention and control of T2DM. Scope and approach: In this review, the improvements and the potential mechanisms of sulforaphane, especially in insulin resistance, glucose metabolism, lipid metabolism, oxidative stress, and inflammatory factors are described. In addition, this review emphasizes the effects of sulforaphane on T2DM complications, such as nephropathy, retinopathy, neuropathy, cardiovascular dysfunction, and tissue fibrosis. Also, this review provides sufficient evidence for further research and development of sulforaphane as a hypoglycemic drug. Key findings and conclusions: A variety of research has shown that sulforaphane could improve insulin resistance, increase the activity of glucose transporter, promote lipid metabolism, and inhibit the oxidative stress and inflammatory factors mainly by regulating NF-E2p45 related factor 2 pathways. Sulforaphane could also regulate different signal pathways in pancreas, kidney, heart, skeletal muscle, brain, and other organs by acting on various molecular targets and play a beneficial role in T2DM. In conclusion, sulforaphane could be used as a novel small molecule against T2DM.
引用
收藏
页码:397 / 407
页数:11
相关论文
共 50 条
[41]   The PI3K/Akt signaling axis and type 2 diabetes mellitus (T2DM): From mechanistic insights into possible therapeutic targets [J].
Taheri, Rana ;
Mokhtari, Yazdan ;
Yousefi, Amir-Mohammad ;
Bashash, Davood .
CELL BIOLOGY INTERNATIONAL, 2024, 48 (08) :1049-1068
[42]   Autoimmune Aspects of Type 2 Diabetes Mellitus - A Mini-Review [J].
Itariu, Bianca K. ;
Stulnig, Thomas M. .
GERONTOLOGY, 2014, 60 (03) :189-196
[43]   Adiponectin in onset and progression of T2DM with cardiac dysfunction in rats [J].
Gupta, C. ;
Bubber, P. ;
Fahim, M. ;
Saidullah, B. ;
Omanwar, S. .
HUMAN & EXPERIMENTAL TOXICOLOGY, 2020, 39 (11) :1463-1474
[44]   Comparative analysis of the transcriptome of T2DM Bama mini-pigs with T2DM patients [J].
Yan, Xueyu ;
Si, Jinglei ;
Zhong, Fangjie ;
Wu, Yanjun ;
Jiang, Qinyang ;
Guo, Yafen ;
Yang, Xiurong ;
Liang, Jing ;
Lan, Ganqiu .
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2022, 42 (02) :236-244
[45]   A review of type 2 diabetes mellitus and cognitive impairment [J].
Kan, Wen ;
Qu, Meijie ;
Wang, Yunyang ;
Zhang, Xianjun ;
Xu, Lili .
FRONTIERS IN ENDOCRINOLOGY, 2025, 16
[46]   Regulatory MicroRNAs in T2DM and Breast Cancer [J].
Durrani, Ilhaam Ayaz ;
Bhatti, Attya ;
John, Peter .
PROCESSES, 2021, 9 (05)
[47]   The role of uncoupling protein 2 (UCP2) on the development of type 2 diabetes mellitus and its chronic complications [J].
de Souza, Bianca Marmontel ;
Assmann, Tais Silveira ;
Kliemann, Lucia Maria ;
Gross, Jorge Luiz ;
Canani, Luis Henrique ;
Crispim, Daisy .
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2011, 55 (04) :239-248
[48]   Epidemiology of cardiovascular complications in type 2 diabetes mellitus [J].
J. B. Meigs .
Acta Diabetologica, 2003, 40 :s358-s361
[49]   Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review [J].
Romeo, Mario ;
Di Nardo, Fiammetta ;
Napolitano, Carmine ;
Basile, Claudio ;
Palma, Carlo ;
Vaia, Paolo ;
Dallio, Marcello ;
Federico, Alessandro .
DIABETOLOGY, 2025, 6 (08)
[50]   Epidemiology of cardiovascular complications in type 2 diabetes mellitus [J].
Meigs, JB .
ACTA DIABETOLOGICA, 2003, 40 (Suppl 2) :S358-S361